Optimizing Clinical Outcomes by Optimizing the Management of Hyperlipidemia is organized by C3-Interventional Academy.

Release Date: Jan 01, 2020
Expiration Date: Feb 29, 2020

Target Audience:
This activity is designed for attendees of C3 Annual Meeting and other clinicians: interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, primary care physicians, technologists and nurses who manage thrombotic risks across diverse patient populations.

Ciné-Med designates this enduring material for a maximum of 1.5 AMA PRA Category 1Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Objectives:
Upon completion of this activity learners should be able to:
• Describe the relationship between LDL-C and cardiovascular disease as well as the substantial residual risk among patients receiving statin therapy.
• Discuss PCSK9 inhibition as a novel mechanism to reduce LDL-C and improve cardiovascular outcomes.
• Identify the impact of PCSK9 inhibitors on coronary plaque, clinical outcomes, and safety, in particular neurocognitive events.
• Describe recent ACC/AHA guidelines for the management of hyperlipidemia in the context of clinical cases.

Additional details will be posted as soon as information is available.

Intended Audience


Activity Payment Details

Activity Fee : NA

Rate this CME (Min 1 - Max 5)

Fee and expenses:
CME credits:
Program contents:
Write Your Review

Reviews Given by Professionals

No Reviews available. Be the first to write a review.

Privacy Policy

Read eMedEvents Privacy Policy


C3-Interventional Academy

View Organizer Details


773-714-0705, ext. 205